Novaliq GmbH Announces European Market Approval for NovaTears™ OTC

Published: Jul 23, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

HEIDELBERG, Germany--(BUSINESS WIRE)--Novaliq GmbH, a drug delivery company with a focus on the topical application of ophthalmic technologies for poorly soluble drugs, today announced the successful CE mark approval for the first topical eye lubricant based on Novaliq’s proprietary technology EyeSol™. NovaTears™ OTC is a multi-dose, non-aqueous, non-blurring and preservative-free topical eye drop for lubrication of the ocular surface. “We are pleased to receive CE mark approval for our first ophthalmic product designed to improve the quality of life for the dry eye OTC patient,” said Bernhard Guenther, CEO of Novaliq GmbH. “It offers a significant new product choice for the European consumer; innovative Novaliq technology that contains no preservatives, yet is available in conventional, multi-dose bottles. The absence of irritating surfactants and preservatives provides dry eye patients improved tolerability and convenience.”

Help employers find you! Check out all the jobs and post your resume.

Back to news